Lomond Therapeutics Holdings, Inc. financial data

Location
Dover, DE
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 66% %
Debt-to-equity 34% %
Return On Equity -105% % -138%
Return On Assets -79% % 99%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32,198,214 shares 544%
Common Stock, Shares, Outstanding 32,198,214 shares 544%
Entity Public Float $0 USD
Common Stock, Value, Issued $3,220 USD 544%
Weighted Average Number of Shares Outstanding, Basic 32,198,214 shares 4142%
Weighted Average Number of Shares Outstanding, Diluted 32,198,214 shares 4142%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $26,110,460 USD 75%
General and Administrative Expense $4,505,726 USD 434%
Operating Income (Loss) $30,616,185 USD -74%
Nonoperating Income (Expense) $68,249 USD
Net Income (Loss) Attributable to Parent $29,782,887 USD -59%
Earnings Per Share, Basic 7 USD/shares 97%
Earnings Per Share, Diluted 7 USD/shares 97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $10,416,252 USD
Assets, Current $2,269 USD 14%
Assets $2,269 USD 14%
Accounts Payable, Current $1,507,813 USD
Accrued Liabilities, Current $100,000 USD
Liabilities, Current $7,220,215 USD 5124%
Liabilities $10,316,529 USD 7365%
Retained Earnings (Accumulated Deficit) $45,015,288 USD -39385%
Stockholders' Equity Attributable to Parent $22,690,214 USD
Liabilities and Equity $2,269 USD 14%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $704,951 USD -437%
Net Cash Provided by (Used in) Financing Activities $15,000 USD -14%
Net Cash Provided by (Used in) Investing Activities $10,063,562 USD
Common Stock, Shares Authorized 300,000,000 shares 500%
Common Stock, Shares, Issued 32,198,214 shares 544%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10,416,252 USD 188%
Deferred Tax Assets, Valuation Allowance $11,136,041 USD 65%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross $11,136,041 USD 65%
Deferred Tax Assets, Operating Loss Carryforwards $3,361,350 USD 54%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $87,239,427 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%